Colorectal cancer， a leading malignant gastrointestinal tumor globally in terms of incidence and mortality， has seen a consistent annual rise in newly diagnosed cases. While conventional therapies like radiotherapy， chemotherapy， and surgery are available， problems such as lack of early diagnosis， poor prognosis， and drug resistance remain significant burdens for patients. Given the complex and diverse pathogenesis of colorectal cancer， there is an urgent clinical need for safe， effective， reliable， and multi-targeted therapeutic strategies. The Hippo signaling pathway， closely linked to mechanisms like tumorigenesis， cancer cell invasion， migration， and drug resistance， extensively participates in the occurrence and development of colorectal cancer， so targeting the signaling pathway for cancer prevention and treatment has become a crucial research direction in recent years. Traditional Chinese medicine （TCM） offers multi-faceted， multi-pathway， and multi-target advantages and becomes an important therapy for colorectal cancer by enhancing patients' immunity， improving the life quality， and prolonging survival. Studies show that the active components of TCM， including flavonoids， terpenoids， phenols， alkaloids， quinones， lignans， and saponins， as well as TCM compounds such as modified Sijunzi decoction， Jiedu Sangen decoction， Jianpi Jiedu compound， and Quyu Jiedu decoction， exhibit significant targeting effects on the Hippo signaling pathway. These TCMs can exert an anti-colorectal cancer effect through various mechanisms， such as inducing cancer cell autophagy and apoptosis， inhibiting epithelial-mesenchymal transition， reversing drug resistance of the tumor， and blocking the cancer cell cycle. This paper reviewed and analyzed Chinese and international research on the action mechanisms of TCM in regulating the Hippo signaling pathway for the prevention and treatment of colorectal cancer with a comprehensive overview presentation， aiming to provide new references and ideas for the clinical application of TCM and the development of new pharmacological agents in the prevention and treatment of colorectal cancer.

Colorectal cancer， a leading malignant gastrointestinal tumor globally in terms of incidence and mortality， has seen a consistent annual rise in newly diagnosed cases. While conventional therapies like radiotherapy， chemotherapy， and surgery are available， problems such as lack of early diagnosis， poor prognosis， and drug resistance remain significant burdens for patients. Given the complex and diverse pathogenesis of colorectal cancer， there is an urgent clinical need for safe， effective， reliable， and multi-targeted therapeutic strategies. The Hippo signaling pathway， closely linked to mechanisms like tumorigenesis， cancer cell invasion， migration， and drug resistance， extensively participates in the occurrence and development of colorectal cancer， so targeting the signaling pathway for cancer prevention and treatment has become a crucial research direction in recent years. Traditional Chinese medicine （TCM） offers multi-faceted， multi-pathway， and multi-target advantages and becomes an important therapy for colorectal cancer by enhancing patients' immunity， improving the life quality， and prolonging survival. Studies show that the active components of TCM， including flavonoids， terpenoids， phenols， alkaloids， quinones， lignans， and saponins， as well as TCM compounds such as modified Sijunzi decoction， Jiedu Sangen decoction， Jianpi Jiedu compound， and Quyu Jiedu decoction， exhibit significant targeting effects on the Hippo signaling pathway. These TCMs can exert an anti-colorectal cancer effect through various mechanisms， such as inducing cancer cell autophagy and apoptosis， inhibiting epithelial-mesenchymal transition， reversing drug resistance of the tumor， and blocking the cancer cell cycle. This paper reviewed and analyzed Chinese and international research on the action mechanisms of TCM in regulating the Hippo signaling pathway for the prevention and treatment of colorectal cancer with a comprehensive overview presentation， aiming to provide new references and ideas for the clinical application of TCM and the development of new pharmacological agents in the prevention and treatment of colorectal cancer.

Colorectal cancer is a common malignant tumor of the digestive system. In recent years， its incidence rate and mortality are increasing year by year. Due to the complex pathogenesis and poor prognosis of patients， colorectal cancer poses a serious threat to human physical and mental health. Currently， although Western medicine treatment methods can to some extent inhibit tumor growth and alleviate patient symptoms， postoperative recurrence， metastasis， multiple adverse reactions， and susceptibility to drug resistance are prominent issues， resulting in unsatisfactory overall treatment outcomes. Therefore， exploring more efficient and safe treatment methods has become an urgent task. The adenosine monophosphate-activated protein kinase （AMPK） signaling pathway plays a regulatory role in the growth， differentiation， apoptosis， and autophagy of colorectal cancer cells， and is widely involved in the occurrence and development of colorectal cancer. It is considered an important target for colorectal cancer treatment. Traditional Chinese medicine has unique advantages in the treatment of colorectal cancer， as it can exert its effects through multiple mechanisms and pathways. It can prevent postoperative recurrence and metastasis， reduce adverse reactions to radiotherapy and chemotherapy， and improve patients' quality of life. It has become a key means of treating colorectal cancer. Research has shown that active ingredients in traditional Chinese medicine such as flavonoids， polyphenols， terpenes， and esters， as well as traditional Chinese medicine compounds such as Qingjie Fuzheng Granules and some traditional Chinese medicine extracts， have significant regulatory effects on AMPK and its interaction signaling pathways. They exert their anti-colorectal cancer effects by inducing autophagy and apoptosis in colorectal cancer cells， promoting ferroptosis， inhibiting epithelial-mesenchymal transition， reversing drug resistance， and arresting the cell cycle. This article reviewed and summarized the relevant research on traditional Chinese medicine in the treatment of colorectal cancer in recent years， with a focus on the mechanism of traditional Chinese medicine in regulating the AMPK signaling pathway for the treatment of colorectal cancer. It is expected to provide ideas and references for the development of new drugs for clinical anti-colorectal cancer treatment.

Liver cancer， as a malignant tumor with high incidence and mortality worldwide， has shown a year-by-year increase in both incidence and mortality in China. Currently， Western medicine has achieved certain efficacy in the clinical management of liver cancer in terms of inhibiting tumor growth， alleviating patient symptoms， and delaying disease progression. However， its limitations cannot be ignored. Significant side effects， increasingly severe drug resistance， and limited improvement in patient survival collectively make the overall therapeutic outcomes fall short of ideal expectations. Therefore， exploring more effective and safer treatment strategies has become a critical issue that urgently needs to be addressed in the field of oncology. The adenosine monophosphate-activated protein kinase （AMPK）/mammalian target of rapamycin （mTOR） signaling pathway plays a central regulatory role in the physiological processes of liver cancer cells， including proliferation， differentiation， apoptosis， and autophagy， and is considered a key molecular target for anti-liver cancer therapy. Traditional Chinese medicine （TCM）， characterized by its multi-pathway and multi-mechanism synergistic effects， has become an important component of the current comprehensive treatment system for liver cancer. Among these， TCM monomeric compounds， owing to their well-defined chemical structures and precisely analyzable pharmacological mechanisms， represent an important breakthrough in anti-liver cancer drug development. Studies have shown that various TCM monomeric compounds， including flavonoids， alkaloids， polyphenols， saponins， terpenoids， and quinones， can regulate the AMPK/mTOR signaling pathway and its upstream and downstream protein expression. Through these mechanisms， they induce autophagy and apoptosis in liver cancer cells， inhibit aerobic glycolysis， reverse drug resistance， promote ferroptosis， block epithelial-mesenchymal transition， and inhibit angiogenesis， thereby effectively suppressing the growth and metastasis of liver cancer cells. Based on this， this article systematically reviews recent studies on TCM monomeric compounds in the treatment of liver cancer， and further analyzes in depth their mechanisms in regulating the AMPK/mTOR signaling pathway， so as to provide ideas and references for the development of new anti-liver cancer drugs.

Liver cancer， as a malignant digestive tract tumor with high incidence and mortality rates globally， has witnessed continuous increases in both incidence and mortality in recent years. Although modern medical treatment methods have achieved certain results in disease control， the treatment of liver cancer remains challenging due to the low early diagnosis rate， obvious toxic and side effects， and widespread drug resistance. Against this backdrop， exploring more efficient and safer treatment strategies is of utmost urgency. The Hippo cascade signaling pathway plays a crucial regulatory role in processes such as the proliferation， differentiation， apoptosis， and invasion of liver cancer cells. It is extensively involved in the occurrence and development of liver cancer， serving as an important target for anti-liver cancer treatment research. Traditional Chinese medicine （TCM） can exert anti-liver cancer effects through multiple approaches， mechanisms， and pathways. It has shown remarkable efficacy in preventing postoperative recurrence and metastasis of liver cancer， reducing adverse reactions of radiotherapy and chemotherapy， and improving the quality of life， thus becoming a key component of comprehensive liver cancer treatment. Studies have confirmed that the TCM active components including flavonoids， alkaloids， terpenoids， polyphenols， saponins， and quinones， as well as the TCM compound prescriptions such as compound Banmao capsules， Erzhu Jiedu decoction， Pianzaihuang， and Zhenggan prescription， can effectively regulate the Hippo signaling pathway. They exert significant anti-liver cancer effects through multiple mechanisms， such as inducing autophagy and apoptosis of liver cancer cells， improving macrophage polarization， blocking epithelial-mesenchymal transition， inhibiting glycolytic metabolism， promoting immune cell activation， reversing tumor drug resistance， and arresting the cell cycle. This study used "liver cancer" "Hippo" "signaling pathway" and "traditional Chinese medicine" as the main keywords to search multiple literature databases， including PubMed， CNKI， and VIP. By discussing and analyzing the mechanisms of TCM in regulating the Hippo signaling pathway for the treatment of liver cancer in the past five years， this paper aims to provide ideas and references for the research and development of new anti-liver cancer drugs in clinical practice.

The active components in traditional Chinese medicine （TCM） generally have problems such as poor solubility and low bioavailability， which seriously restrict their clinical efficacy. In recent years， TCM nano-self-assembly based on the non-covalent interactions between molecules has become the research frontier in this field because it can spontaneously form an orderly structure and improve the insoluble components in the body. Moreover， TCM nano-self-assembly has shown unique advantages in the treatment of fibrosis， inflammatory and immune diseases， infectious diseases， and cancer. This article summarizes the research context， structural system， and potential as a pharmacological substance basis of TCM nano-self-assembly by reviewing recent published studies， with focuses on the application of TCM nano-self-assembly in the treatment of diseases from single components to complex systems. In addition， this article summarizes its advantages， mechanism characteristics， and main challenges faced. At present， this field still faces issues such as insufficient mechanism research， a lack of in-depth understanding of the competitive assembly rules of multiple components， difficulty in quality control， unclear in vivo processes and safety， and obstacles to clinical translation. To address these issues， this article proposes a series of solutions， including introducing molecular dynamics simulation and artificial intelligence to predict assembly behavior， using experimental techniques to analyze non-covalent interactions， establishing a comprehensive evaluation system with multiple indicators， using isotope labeling and in vivo imaging techniques to dynamically track in vivo processes， conducting standardized safety evaluation， promoting the filing of hospital preparations and new drug applications， and strengthening early communication between research and regulation. Finally， this article points out the future development directions， aiming to provide reference for subsequent research and clinical translation.

The active components in traditional Chinese medicine （TCM） generally have problems such as poor solubility and low bioavailability， which seriously restrict their clinical efficacy. In recent years， TCM nano-self-assembly based on the non-covalent interactions between molecules has become the research frontier in this field because it can spontaneously form an orderly structure and improve the insoluble components in the body. Moreover， TCM nano-self-assembly has shown unique advantages in the treatment of fibrosis， inflammatory and immune diseases， infectious diseases， and cancer. This article summarizes the research context， structural system， and potential as a pharmacological substance basis of TCM nano-self-assembly by reviewing recent published studies， with focuses on the application of TCM nano-self-assembly in the treatment of diseases from single components to complex systems. In addition， this article summarizes its advantages， mechanism characteristics， and main challenges faced. At present， this field still faces issues such as insufficient mechanism research， a lack of in-depth understanding of the competitive assembly rules of multiple components， difficulty in quality control， unclear in vivo processes and safety， and obstacles to clinical translation. To address these issues， this article proposes a series of solutions， including introducing molecular dynamics simulation and artificial intelligence to predict assembly behavior， using experimental techniques to analyze non-covalent interactions， establishing a comprehensive evaluation system with multiple indicators， using isotope labeling and in vivo imaging techniques to dynamically track in vivo processes， conducting standardized safety evaluation， promoting the filing of hospital preparations and new drug applications， and strengthening early communication between research and regulation. Finally， this article points out the future development directions， aiming to provide reference for subsequent research and clinical translation.

This study addresses the issue of disability risk among elderly individuals in the context of population aging. Through investigations conducted at 27 retirement cadre centers in Beijing and based on multidisciplinary team collaboration, a closed-loop health management service model was established, incorporating comprehensive geriatric assessment, personalized interventions, and dynamic follow-up. Preliminary implementation results demonstrate that this model can effectively identify high-risk elderly individuals, while improving both participation rates in interventions among the elderly and risk identification capabilities among healthcare professionals.

Enhanced recovery after surgery (ERAS) is a series of perioperative optimization measures based on evidence-based medicine aimed at achieving rapid recovery. Existing studies have shown that ERAS can effectively reduce surgical stress, decrease the incidence of complications, shorten hospital stays, save medical costs, and improve patient satisfaction. Although lung transplantation techniques have become increasingly mature, lung transplant recipients still have a high incidence of complications during perioperative period. To further improve the perioperative survival rate of lung transplant recipients, introducing ERAS concept into the perioperative management strategy of lung transplantation is of great significance for reducing incidence of perioperative complications, promoting rapid recovery and long-term survival of lung transplant recipients. This article discusses the advances in application of ERAS concept in the perioperative management of lung transplantation, aiming to provide references for optimizing the perioperative management of lung transplant recipients and reducing perioperative complications.